Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Who Should Administer Anti-Aging Treatments
Why 50mg is the standard vial size Common GHK-Cu vial sizes: 50mg (most popular) 100mg (economy size) 200mg (bulk) 10mg, 20mg (smaller, less common) Why 50mg is ideal: Perfect for 5-10 week protocol Lasts 25-50 doses (depending on dose used) Not too expensive (most 50mg vials $80-150) Easy reconstitution math Reasonable commitment (test if it works for you) Fits standard protocols Cost per dose from 50mg: If vial costs $100 Gives 25 doses at 2mg each = $4 per dose Very affordable for anti-aging Injectable vs topical GHK-Cu Injectable (most powerful): Systemic effects throughout body 80-90% bioavailability Works on skin from inside out Dose: 1-3mg, 3-7x weekly Best for comprehensive anti-aging Topical (easiest): Applied to skin surface Lower absorption (1-2% concentration in serum) Works locally on skin Daily application Best for focused skin improvement Can combine with injectable Which to choose: Injectable: Serious anti-aging, whole-body benefits Topical: Easier, good for skin-only goals Both: Maximum results See our copper peptides GHK-Cu guide , glow peptides guide , glow peptides , and injectable vs oral peptides
At Veritas Medical Center, we offer powerful, science-backed Vitamin Injections and IV Therapies that restore your bodys nutritional balance quickly and effectivelyso you can feel vibrant, focused, and energized again
Key Takeaways ARA-290 (cibinetide) is derived from erythropoietin without erythropoietic effects It activates the innate repair receptor It reduces inflammation while preserving immune function It supports nerve repair and tissue protection It has been studied extensively in neuropathic and inflammatory conditions It fits naturally into an integrative medicine framework The Bigger Picture ARA-290 represents a shift away from symptom-focused medicine toward cellular repair biology
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
